EDGAR Filing Documents for 0001144204-13-016759

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:

SEC Accession No. 0001144204-13-016759

Filing Date

2013-03-22

Accepted

2013-03-21 20:36:08

Documents

Period of Report

2012-12-31

Document Format Files

Seq	Description	Document	Type	Size
1	20-F	v338855_20f.htm	20-F	1685811
2	EXHIBIT 12.1	v338855_ex12-1.htm	EX-12.1	6729
3	EXHIBIT 12.2	v338855_ex12-2.htm	EX-12.2	7052
4	EXHIBIT 13.1	v338855_ex13-1.htm	EX-13.1	5216
5	EXHIBIT 13.2	v338855_ex13-2.htm	EX-13.2	4988
6	GRAPHIC	tlogo2.jpg	GRAPHIC	14258
	Complete submission text file	0001144204-13-016759.txt		1730582

Mailing Address C/O MARK COHEN, CHAIRMAN, PEARL COHEN 1500 BROADWAY, 12TH FLOOR NEW YORK NY 10036

Business Address 53 DAVIES STREET LONDON X0 W1K 5JH 646-878-0804

Morria Biopharmaceuticals PLC (Filer) CIK: 0001541157 (see all company filings)

IRS No.: 981034922 | State of Incorp.: X0
Type: 20-F | Act: 34 | File No.: 000-54749 | Film No.: 13708959
SIC: 2834 Pharmaceutical Preparations